Processing timeline
1
days
Filed
21 July 2026
Decision Due
1 Sept 2026
Est decision date: 22 Aug 2026. Based on 46 decided Professional & Business Services notifications.
Acquirer(s)
Vertex Pharmaceuticals Incorporated EIN - 04-3039129
Target(s) or Vendor(s)
Crinetics Pharmaceuticals Inc. EIN 26-3744114
Other parties
Clark Merger Sub, Inc DE File Number: 10678660
US-based biotechnology company Vertex Pharmaceuticals Incorporated proposes to acquire 100% of the shares in US-based pharmaceutical company Crinetics Pharmaceuticals, Inc. Vertex develops treatments for serious diseases, with products supplied in Australia. Crinetics focuses on endocrine diseases.
Vertex Pharmaceuticals Incorporated ( Vertex ) proposes to acquire 100% of the issued shares in Crinetics Pharmaceuticals, Inc. ( Crinetics ) (the Acquisition ). Vertex is a US-based biotechnology company, listed on the Nasdaq Global Select Market under the symbol “VRTX”, that develops, manufactures and markets a range of pharmaceutical products for serious diseases. It currently has 7 approved products for the treatment of cystic fibrosis, sickle cell disease, transfusion dependent beta thalassemia, and acute pain (including 5 that are approved by the Therapeutic Goods Administration (TGA) and supplied in Australia). It also has certain products currently in development stages for other serious diseases. Crinetics is a US-based pharmaceutical company, listed on the Nasdaq Global Select Market under the ticker symbol “CRNX”, that has a focus on discovering, developing, and commercialising treatments for endocrine diseases. Crinetics has one product on market in the US, Palsonify (paltusotine), a prescription oral medication used to treat acromegaly, a rare hormonal disorder. Palsonify is not currently approved or under review for approval by the TGA for supply in Australia. Crinetics also has a range of products currently in development stages in the endocrinology, endocrine-driven oncology and metabolic diseases spaces.
The ACCC has prepared a questionnaire on the Acquisition. Submissions or information in response to the questionnaire should be provided by 29 July 2026 via email to mergers@accc.gov.au with the title Submission re: Vertex - Crinetics . The ACCC’s ability to give detailed consideration to submissions received after this time may be limited.